Children’s Hospital Los Angeles (CHLA) is now offering Casgevy (exagamglogene autotemcel), an approved gene-editing therapy for sickle cell…
Articles by Marisa Wexler, MS
The Bill and Melinda Gates Foundation is investing up to $50 million in Tessera Therapeutics to support the development…
A newborn screening program in Catalonia improved outcomes for children with sickle cell disease (SCD), with patients being…
Most people with sickle cell disease (SCD) who received the gene-editing therapy Casgevy (exagamglogene autotemcel) in clinical trials…
The vast majority of people with sickle cell disease (SCD) who received the now-approved gene therapy Lyfgenia (lovotibeglogene…
Kanglin Biotechnology has raised $20 million in financing to advance the development of KL003, an experimental gene therapy for…
Two centers in California are enrolling nine people with severe sickle cell disease (SCD) for a clinical trial of…
The Clinton Health Access Initiative (CHAI) is leading a project that aims to expand access to diagnostic tests and treatments…
Editas Medicine has announced proof-of-concept data for a new gene-editing approach for sickle cell disease (SCD) that does…
Patient enrollment has been completed for the Phase 3 RISE UP study, a clinical trial that’s assessing the safety and…